Liquidia Files Appeal of Ruling Lung Drug Infringes UTC’s Patent

Liquidia Corp. launched its appeal Friday of a Delaware federal judge’s ruling that found its Yutrepia drug infringes a patent for United Therapeutics Corp.’s competing treatment for high blood pressure in the lungs despite a tribunal’s earlier cancellation of the patent.

The notice of appeal, filed in the US District Court for the District of Delaware, comes one week after Liquidia asked Judge Richard G. Andrews to partially stay enforcement of his final judgment, issued earlier the same day, so regulators potentially can approve its Yutrepia before the expiration of the patent for UTC’s Tyvaso.

On July 19, the ...